Everolimus Trial in Laryngotracheal Stenosis

Inclusion Criteria: * Current diagnosis of laryngotracheal stenosis * Patient age 18 - 80 years old * Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1 * Serum total bilirubin and Serum Glutamic Pyruvic Transaminase (SGPT)/(ALT) \< 2.0 times the upper limit of normal; * Serum creatinine \< 2.0 mg/dL; * The patient must be able to comprehend and have signed the informed consent. * The patient must have documentation of their date of laryngotracheal stenosis diagnosis and prior medical/surgical history. * Participants must have also had a prior suspension microlaryngoscopy with endoscopic excision of scar and balloon dilation procedure prior to study entry Exclusion Criteria: * Use of corticosteroids (glucocorticoids) within 7 days of everolimus administration (except physiologic dose equivalent) * Infection requiring treatment with antibiotics, antifungal, or antiviral agents within 7 days of registration * Participation in any clinical trial within 21 days of bone marrow collection involving an investigational drug or device * History of malignancy within five years of registration, except adequately treated basal or squamous cell skin cancer * History of an autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus) requiring active systemic treatment. Hypothyroidism without evidence of Grave's disease or Hashimoto's thyroiditis is permitted. * Human T-cell Lymphotropic Virus type 1 (HTLV-1) or type 2 (HTLV-2) * Ne…